Tag: BB-1701
Unlocking the Potential of Antibody-drug Conjugates
One hundred years ago, Paul Ehrlich*, a German biochemist and Nobel laureate who created the field of chemotherapy, coined the term “magic bullet.” He...
Eisai & Co and Bliss Biopharmaceutical (Hangzhou) Sign Agreement to Jointly...
Japanese drugmaker Eisai & Co and Chinese drug developer Bliss Biopharmaceutical (Hangzhou) Co., have entered into a joint development agreement to further develop BB-1701, an antibody-drug conjugate (ADC). As part of the agreement Eisai & Co obtained option rights for a strategic collaboration.